Quick Answer
RECURSION PHARMACEUTICALS, INC. reported R&D Expense of $475.27 million for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $475.27M | +51.2% |
| 2024 | $314.42M | +30.3% |
| 2023 | $241.23M | +54.9% |
| 2022 | $155.70M | +15.1% |
| 2021 | $135.27M | +113.6% |
| 2020 | $63.32M | +38.2% |
| 2019 | $45.81M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $121.06M | +62.3% | -5.9% |
| June 30, 2025 | $128.64M | +74.0% | -0.8% |
| March 31, 2025 | $129.63M | +91.9% | +73.8% |
| September 30, 2024 | $74.60M | +6.6% | +0.9% |
| June 30, 2024 | $73.93M | +34.3% | +9.4% |
| March 31, 2024 | $67.56M | +44.7% | -3.5% |
| September 30, 2023 | $70.01M | +71.4% | +27.1% |
| June 30, 2023 | $55.06M | +43.2% | +18.0% |
- RECURSION PHARMACEUTICALS, INC. showed an increase of +51.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, RECURSION PHARMACEUTICALS, INC.’s r&d expense has grown by 937.5% (from $45.81 million to $475.27 million).
- The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: